COGT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COGT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Cogent Biosciences is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, Cogent Biosciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Risk Assessment falls into.
Cogent Biosciences (NAS:COGT) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Cogent Biosciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Fairmount Funds Management Llc | 10 percent owner, other: See Remarks | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Evan Kearns | officer: Chief Legal Officer | AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421 |
John L. Green | officer: Chief Financial Officer | MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139 |
John Edward Robinson | officer: Chief Scientific Officer | C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140 |
Christopher W. Cain | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Peter Evan Harwin | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Arlene Morris | director | C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304 |
Todd Shegog | director | 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139 |
Jessica Sachs | officer: Chief Medical Officer | C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Matthew Ros | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Karen Jean Ferrante | director | 150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818 |
Andrew R Robbins | director, officer: President and CEO | C/O 3200 WALNUT ST, BOULDER CO 80301 |
Venrock Healthcare Capital Partners Iii, L.p. | 10 percent owner | 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036 |
Vhcp Management Iii, Llc | 10 percent owner | 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
Vhcp Management Ii, Llc | 10 percent owner | 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-09-2023
By sperokesalga sperokesalga • 04-12-2023
By Value_Insider Value_Insider • 11-14-2022
By GlobeNewswire GlobeNewswire • 06-03-2023
By Value_Insider Value_Insider • 11-28-2022
By Value_Insider Value_Insider • 11-03-2022
By Value_Insider Value_Insider • 11-09-2022
By sperokesalga sperokesalga • 05-23-2023
By Stock market mentor Stock market mentor • 02-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.